Current ADC Practice in Cervical Cancer

In cervical cancer, antibody drug conjugates are presented as an important advance in a disease where treatment options after progression have historically been limited. The faculty review tisotumab vedotin as a meaningful alternative to traditional single agent chemotherapy in recurrent disease and discuss trastuzumab deruxtecan as a possible option for the smaller group of patients with HER2 expressing tumors. Interest in additional targets, including TROPE2, suggests that the treatment landscape may continue to broaden, but current clinical use still depends heavily on thoughtful toxicity management and patient selection. Ocular adverse events, neuropathy, bleeding, and mucosal complications are emphasized as practical issues that can affect quality of life and treatment continuity if not addressed early. The conversation frames antibody drug conjugates not simply as new drugs, but as therapies that require preparation, education, and multidisciplinary coordination to use well. That balance between efficacy and tolerability becomes a recurring theme as the discussion turns to confirmatory data and real world clinical experience.